Product Information
Registration Status: ActiveSIN13374P
CERVARIX (PREFILLED SYRINGE) is approved to be sold in Singapore with effective from 2007-11-22. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN13374P.
This product contains Human Papillomavirus Type 16 L1 20mcg/0.5ml, and Human Papillomavirus Type 18 L1 20mcg/0.5ml in the form of INJECTION, SUSPENSION. It is approved for INTRAMUSCULAR use.
This product is manufactured by GlaxoSmithKline Biologicals s.a.
GlaxoSmithKline Biologicals s.a. in BELGIUM.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Active Ingredient/Synonyms
L1 protein, Human papillomavirus type 16 Vaccine | Recombinant human papillomavirus type 16 L1 protein | Human papillomavirus type 16 L1 capsid protein antigen |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Active Ingredient/Synonyms
L1 protein, Human papillomavirus type 18 Vaccine | Recombinant human papillomavirus type 18 L1 protein | Human papillomavirus type 18 L1 capsid protein antigen |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.